Market capitalization | $7.91b |
Enterprise Value | $7.80b |
P/E (TTM) P/E ratio | 595.01 |
EV/FCF (TTM) EV/FCF | 70.51 |
EV/Sales (TTM) EV/Sales | 6.88 |
P/S ratio (TTM) P/S ratio | 6.98 |
P/B ratio (TTM) P/B ratio | 6.81 |
Revenue growth (TTM) Revenue growth | 20.89% |
Revenue (TTM) Revenue | $1.13b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
18 Analysts have issued a Penumbra, Inc. forecast:
18 Analysts have issued a Penumbra, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,134 1,134 |
21%
21%
|
|
Gross Profit | 699 699 |
20%
20%
|
|
EBITDA | 106 106 |
71%
71%
|
EBIT (Operating Income) EBIT | 74 74 |
104%
104%
|
Net Profit | 14 14 |
51%
51%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
Head office | United States |
CEO | Adam Elsesser |
Employees | 4,200 |
Founded | 2004 |
Website | www.penumbrainc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.